Skip to main content

Parkinson's Disease clinical trials at UC Health
30 in progress, 13 open to new patients

  • A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

    open to eligible people ages 30-85

    The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).

    at UC Irvine

  • A Study of LY3154207 in Participants With Parkinson's Disease Dementia

    open to eligible people ages 40-85

    A randomized placebo-controlled trial in individuals with Parkinson's disease dementia to evaluate the safety and efficacy of three doses of study drug LY3154207 in participants with mild-to-moderate Parkinson's disease dementia treated for 12 weeks.

    at UC Irvine UC Davis

  • A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

    open to eligible people ages 40-80

    This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2).

    at UCSF

  • An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

    open to eligible people ages 18 years and up

    A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.

    at UC Irvine

  • Cognitive Rehabilitation for PD-MCI

    open to eligible people ages 40 years and up

    To investigate the effectiveness of a novel compensatory cognitive rehabilitation program for individuals with Parkinson's disease (PD) and mild cognitive impairment (MCI).

    at UCSD

  • Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease

    open to eligible people ages 18 years and up

    Parkinson's disease (PD) is a neurological disorder that puts individuals at high risk for injuries and long-term disabilities as a result of a fall or other trauma. Injuries sustained from falls account for many deaths as well as thousands of hospital admissions and nursing home stays every month. Quality of life and even longevity itself is reduced due to the resulting surgeries, immobility, complications and even cognitive impairments that can follow. The proposed study will explore beneficial impact of a treatment modality (OMM/OMT) that may significantly reduce the morbidity of this condition by comparing 6 weeks of OMT versus 6 weeks light touch intervention versus 6 weeks care as usual to improve gait in individuals with PD. Gait will be measured at mid-treatment, post-treatment and 4-week follow-up.

    at UCSD

  • Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

    open to eligible people ages 40-80

    To evaluate the dose-related safety of BIIB054, to evaluate the pharmacodynamic effects of BIIB054 on the integrity of nigrostriatal dopaminergic nerve terminals, to assess the pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054.

    at UCSF

  • Invasive Approach to Model Human Cortex-Basal Ganglia Action-Regulating Networks

    open to eligible people ages 18 years and up

    The brain networks controlling movement are complex, involving multiple areas of the brain. Some neurological diseases, like Parkinson's disease, cause abnormalities in the brain networks. Deep brain stimulation is a treatment that is used to treat these types of neurological diseases. Through this research, the investigators will take advantage of the unique opportunity provided by awake deep brain stimulation surgery to learn more about how the brain functions in a diseased state and how deep brain stimulation changes these networks. This study aims to enroll up to 75 subjects over a period of 2.5 years. Those who participate in the study will spend up to 40 minutes during their deep brain stimulation surgery during which researchers will record signals from deep structures within the brain as well as the surface of the brain using electrodes that are temporarily placed for research purposes. During the study, researchers will record signals while subjects perform three different tasks, in some cases while the brain is stimulated. Study participation is limited to the intraoperative environment with no additional study visits required.

    at UCLA UCSF UCSD

  • Low Frequency Deep Brain Stimulation of cognitive performance in Parkinson's Disease

    “Research evaluating memory and thinking ability”

    open to eligible people ages 18 years and up

    Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease. All study participants have undergone DBS implantation surgery as part of their routine care for motor manifestations of Parkinson's disease. In this study, a temporary low frequency period of stimulation will be applied to determine its effects on cognition.

    at UC Davis

  • More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

    open to eligible people ages 18-105

    This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).

    at UCSF

  • Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

    open to eligible people ages 30 years and up

    This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.

    at UCSD

  • The Parkinson's Genetic Research Study

    open to eligible people ages 18 years and up

    The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.

    at UCSD

  • VY-AADC02 for Parkinson's Disease With Motor Fluctuations

    open to eligible people ages 40-75

    The objectives of this study are to assess the distribution, efficacy, and safety of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

    at UCSF

  • A Study to Test the Safety and Effectiveness of the Experimental "Accordion Pill" in Patients with Advanced Parkinson's Disease

    “The Accordion PillTM extends the activity and effectiveness of Parkinson's Disease medication, keeping the drug in the stomach for longer.”

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor fluctuations such as "off time" in advanced Parkinson's Disease patients.

    at UC Davis

  • Antigen Presentation and Lymphocyte Response in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief questionnaires and a blood draw of 30 mL (approximately 2 tablespoons) to be collected.

    at UCSD

  • Closed Loop Deep Brain Stimulation in Parkinson's Disease

    Sorry, not yet accepting patients

    This is an exploratory pilot study to test a variety of strategies for feedback-controlled deep brain stimulation. Twenty Parkinson's disease patients with motor fluctuations and will be implanted bilaterally with a totally internalized bidirectional neural interface, Medtronic Activa RC+S. Each RC+S will be attached to both quadripolar subthalamic DBS lead, and quadripolar subdural cortical paddle lead. Investigators will collect and characterize each subject's physiological biomarkers related to the hypokinetic and hyperkinetic state to prototype classifier/control algorithms both in vitro and during a brief in-clinic test in study subjects. There will be a small pilot clinical trial in which individualized classifier/control strategies for each hemisphere in each subject will be embedded within the RC+S for one month of feedback-controlled stimulation, to be compared with one month of empirically optimized open-loop stimulation, administered in randomized order with closed-loop stimulation.

    at UCSF

  • Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients

    Sorry, accepting new patients by invitation only

    This study will investigate cortical stimulation to treat mood and behavioral symptoms in Parkinson's disease patients.

    at UCSF

  • Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.

    at UCSF

  • Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?

    Sorry, in progress, not accepting new patients

    The purpose of this study is to improve outcomes for persons living with Parkinson's Disease (PD) and their family caregivers. The investigators hypothesize that outpatient interdisciplinary palliative care will improve patient-centered outcomes for PD patients at high-risk for poor outcomes.

    at UCSF

  • Efficacy of Isradipine in Early Parkinson Disease

    Sorry, in progress, not accepting new patients

    The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

    at UCSF UC Irvine UCSD

  • Exercise Targeting Cognitive Impairment in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on mild cognitive impairment (MCI) of the executive function (EF) subtype in Parkinson's disease (PD); we hypothesize that skill-based exercise will result in the greatest improvement in EF and lead to modification of underlying neural substrates.

    at UCLA

  • Infusion of Apomorphine: Long-term Safety Study

    Sorry, in progress, not accepting new patients

    This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

    at UCLA

  • Microbiota Intervention to Change the Response of Parkinson's Disease

    Sorry, not yet accepting patients

    The clinical phenotype of Parkinson's disease (PD) is quite variable, as is the response to and side effects from medications. While many patients respond to carbidopa/levodopa early on, motor fluctuations and dyskinesias can become a problem as the condition progresses, causing significant impairment in function and quality of life. The gut microbiome is of increasing interest in PD, potentially contributing to pathophysiology and clinical phenotype. Furthermore, gut bacteria are capable of metabolizing levodopa, which may decrease its ability to reach the central nervous system and could explain the variable effect seen clinically. Altering the population of drug-metabolizing bacteria could improve the clinical symptoms of PD and the benefit seen with medications. The investigators hypothesize that the gut microbiome in people with PD correlates with their phenotypic characteristics, which can be improved with targeting the microbiome through dietary or therapeutic interventions. The investigators propose a two-part clinical trial. First, a cross-sectional analysis will correlate the microbiome profile with (a) the clinical phenotype of PD and (b) medication response. Second, a randomized, controlled trial, will evaluate the effect of microbiome manipulation on clinical phenotype and medication response. The investigators plan to reduce the level of bacteria through antibiotic use, resetting the potentially disadvantageous microbiome population. Outcomes will include changes in clinical symptoms, alterations in the the microbiome, and changes in serum markers of inflammation. This thorough characterization will broaden our understanding of the gut-brain axis significantly in PD in clinically relevant ways that have yet to be explored.

    at UCSF

  • North American Prodromal Synucleinopathy Consortium

    Sorry, not currently recruiting here

    This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • Observational, Long-term, Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Studies

    Sorry, accepting new patients by invitation only

    An extension study for participants who have completed VY-AADC01 or VY-AADC02 Studies

    at UCSF

  • Safety and Biomarker Study of EPI-589 in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.

    at UCSF

  • Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease. CERE-120 is an experimental drug that consists of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. Similar to other growth factors (such as GDNF), neurturin is capable of restoring function and protecting brain cells from further damage. The virus used in CERE-120 is not known to cause disease in people. CERE-120 is delivered directly to the brain cells most affected in Parkinson's disease - the dopamine producing neurons. CERE-120 is injected during brain surgery. Once in place, CERE-120 continuously produces neurturin.

    at UCSF

  • Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

    at UCSF

  • Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety study of AADC gene transfer (VY-AADC01) in subjects with Parkinson's disease.

    at UCSF

  • Study of Urate Elevation in Parkinson's Disease, Phase 3

    Sorry, in progress, not accepting new patients

    A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD. Clinical decline will be assessed as change in the primary outcome variable of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale comprising patient- and clinician-reported outcomes.

    at UCSF UCSD UC Davis

Last updated: